CymaBay Therapeutics, Inc. (NASDAQ: CBAY) Stock Competitors & Peer Comparison
See CBAY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CBAY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CBAY | $32.48 | +0.03% | 3.7B | -32.81 | -$0.99 | N/A |
| VRTX | $546.12 | -2.12% | 138.6B | 28.70 | $19.03 | N/A |
| REGN | $827.72 | -1.87% | 85.3B | 18.14 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,033.15 | -1.93% | 64.2B | 93.24 | $11.08 | N/A |
| MRNA | $145.55 | -2.23% | 57.8B | -17.86 | -$8.15 | N/A |
| RVMDW | $11.70 | -2.34% | 46.7B | -1.65 | -$7.21 | N/A |
| RVMD | $210.02 | -0.40% | 44.6B | -23.81 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $358.26 | -1.22% | 38.3B | 63.04 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
CBAY vs VRTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while VRTX trades at $546.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas VRTX's P/E ratio is 28.70. In terms of profitability, CBAY's ROE is -0.64%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, CBAY is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
CBAY vs REGN Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, REGN has a market cap of 85.3B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while REGN trades at $827.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas REGN's P/E ratio is 18.14. In terms of profitability, CBAY's ROE is -0.64%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CBAY is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
CBAY vs VRNA Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CBAY's ROE is -0.64%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, CBAY is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
CBAY vs ARGX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ARGX has a market cap of 64.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ARGX trades at $1,033.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ARGX's P/E ratio is 93.24. In terms of profitability, CBAY's ROE is -0.64%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, CBAY is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
CBAY vs MRNA Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, MRNA has a market cap of 57.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while MRNA trades at $145.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MRNA's P/E ratio is -17.86. In terms of profitability, CBAY's ROE is -0.64%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, CBAY is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
CBAY vs RVMDW Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, RVMDW has a market cap of 46.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while RVMDW trades at $11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RVMDW's P/E ratio is -1.65. In terms of profitability, CBAY's ROE is -0.64%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, CBAY is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
CBAY vs RVMD Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, RVMD has a market cap of 44.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while RVMD trades at $210.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RVMD's P/E ratio is -23.81. In terms of profitability, CBAY's ROE is -0.64%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, CBAY is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
CBAY vs SGEN Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CBAY's ROE is -0.64%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CBAY is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
CBAY vs ONC Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ONC trades at $358.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ONC's P/E ratio is 63.04. In terms of profitability, CBAY's ROE is -0.64%, compared to ONC's ROE of +0.14%. Regarding short-term risk, CBAY is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
CBAY vs ALNY Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ALNY has a market cap of 35.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ALNY trades at $266.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ALNY's P/E ratio is 47.95. In terms of profitability, CBAY's ROE is -0.64%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, CBAY is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
CBAY vs INSM Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, INSM has a market cap of 27.4B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while INSM trades at $126.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas INSM's P/E ratio is -30.73. In terms of profitability, CBAY's ROE is -0.64%, compared to INSM's ROE of -1.11%. Regarding short-term risk, CBAY is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
CBAY vs BNTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, BNTX has a market cap of 26.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while BNTX trades at $103.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BNTX's P/E ratio is -13.46. In terms of profitability, CBAY's ROE is -0.64%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, CBAY is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
CBAY vs INCY Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, INCY has a market cap of 25.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while INCY trades at $126.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas INCY's P/E ratio is 17.04. In terms of profitability, CBAY's ROE is -0.64%, compared to INCY's ROE of +0.30%. Regarding short-term risk, CBAY is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check INCY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
CBAY vs ROIV Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ROIV trades at $34.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ROIV's P/E ratio is -33.23. In terms of profitability, CBAY's ROE is -0.64%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, CBAY is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ROIV's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
CBAY vs UTHR Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, UTHR has a market cap of 20.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while UTHR trades at $487.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas UTHR's P/E ratio is 17.45. In terms of profitability, CBAY's ROE is -0.64%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, CBAY is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
CBAY vs GMAB Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, GMAB has a market cap of 20.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while GMAB trades at $33.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas GMAB's P/E ratio is 25.32. In terms of profitability, CBAY's ROE is -0.64%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, CBAY is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
CBAY vs BGNE Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CBAY's ROE is -0.64%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, CBAY is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
CBAY vs DNA-WT Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CBAY's ROE is -0.64%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, CBAY is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
CBAY vs ASND Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ASND has a market cap of 16.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ASND trades at $270.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ASND's P/E ratio is -111.80. In terms of profitability, CBAY's ROE is -0.64%, compared to ASND's ROE of +1.90%. Regarding short-term risk, CBAY is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
CBAY vs NBIX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while NBIX trades at $155.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas NBIX's P/E ratio is 22.49. In terms of profitability, CBAY's ROE is -0.64%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, CBAY is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
CBAY vs JAZZ Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while JAZZ trades at $246.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas JAZZ's P/E ratio is 9.23. In terms of profitability, CBAY's ROE is -0.64%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, CBAY is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
CBAY vs EXEL Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, EXEL has a market cap of 14.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while EXEL trades at $59.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas EXEL's P/E ratio is 16.86. In terms of profitability, CBAY's ROE is -0.64%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, CBAY is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check EXEL's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
CBAY vs BBIO Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, BBIO has a market cap of 14.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while BBIO trades at $74.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BBIO's P/E ratio is -20.01. In terms of profitability, CBAY's ROE is -0.64%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, CBAY is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
CBAY vs SMMT Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while SMMT trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SMMT's P/E ratio is -15.72. In terms of profitability, CBAY's ROE is -0.64%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, CBAY is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
CBAY vs HALO Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, HALO has a market cap of 13.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while HALO trades at $110.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas HALO's P/E ratio is 20.56. In terms of profitability, CBAY's ROE is -0.64%, compared to HALO's ROE of +1.81%. Regarding short-term risk, CBAY is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CBAY vs BMRN Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while BMRN trades at $66.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BMRN's P/E ratio is 31.99. In terms of profitability, CBAY's ROE is -0.64%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, CBAY is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
CBAY vs KRTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CBAY's ROE is -0.64%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CBAY is less volatile compared to KRTX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
CBAY vs MDGL Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while MDGL trades at $541.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MDGL's P/E ratio is -42.27. In terms of profitability, CBAY's ROE is -0.64%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, CBAY is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
CBAY vs ARWR Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ARWR trades at $86.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ARWR's P/E ratio is -38.37. In terms of profitability, CBAY's ROE is -0.64%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, CBAY is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ARWR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
CBAY vs TECH Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while TECH trades at $72.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TECH's P/E ratio is 37.34. In terms of profitability, CBAY's ROE is -0.64%, compared to TECH's ROE of +0.09%. Regarding short-term risk, CBAY is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
CBAY vs RNAM Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CBAY's ROE is -0.64%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CBAY is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
CBAY vs AXSM Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while AXSM trades at $206.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas AXSM's P/E ratio is -53.96. In terms of profitability, CBAY's ROE is -0.64%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, CBAY is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
CBAY vs KRYS Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, KRYS has a market cap of 10.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while KRYS trades at $358.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas KRYS's P/E ratio is 44.89. In terms of profitability, CBAY's ROE is -0.64%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CBAY is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check KRYS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
CBAY vs PRAX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, PRAX has a market cap of 9.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while PRAX trades at $351.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PRAX's P/E ratio is -27.21. In terms of profitability, CBAY's ROE is -0.64%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, CBAY is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check PRAX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
CBAY vs KYMR Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while KYMR trades at $117.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas KYMR's P/E ratio is -36.68. In terms of profitability, CBAY's ROE is -0.64%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, CBAY is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check KYMR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
CBAY vs IONS Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, IONS has a market cap of 9.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while IONS trades at $58.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas IONS's P/E ratio is -33.77. In terms of profitability, CBAY's ROE is -0.64%, compared to IONS's ROE of -1.11%. Regarding short-term risk, CBAY is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check IONS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
CBAY vs RXDX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CBAY's ROE is -0.64%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CBAY is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
CBAY vs PTGX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, PTGX has a market cap of 9.4B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while PTGX trades at $145.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PTGX's P/E ratio is 141.48. In terms of profitability, CBAY's ROE is -0.64%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, CBAY is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
CBAY vs NUVL Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas NUVL's P/E ratio is -21.79. In terms of profitability, CBAY's ROE is -0.64%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CBAY is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check NUVL's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
CBAY vs CYTK Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while CYTK trades at $72.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CYTK's P/E ratio is -10.07. In terms of profitability, CBAY's ROE is -0.64%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, CBAY is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check CYTK's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
CBAY vs CRNX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CRNX's P/E ratio is -16.86. In terms of profitability, CBAY's ROE is -0.64%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CBAY is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check CRNX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
CBAY vs PCVX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while PCVX trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PCVX's P/E ratio is -8.02. In terms of profitability, CBAY's ROE is -0.64%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, CBAY is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
CBAY vs IMGN Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CBAY's ROE is -0.64%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CBAY is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
CBAY vs TGTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while TGTX trades at $55.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TGTX's P/E ratio is 20.28. In terms of profitability, CBAY's ROE is -0.64%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, CBAY is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check TGTX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
CBAY vs IBRX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while IBRX trades at $8.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas IBRX's P/E ratio is -8.33. In terms of profitability, CBAY's ROE is -0.64%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, CBAY is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check IBRX's competition here
Abivax S.A. (NASDAQ: ABVX)
CBAY vs ABVX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ABVX has a market cap of 8.4B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ABVX trades at $114.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ABVX's P/E ratio is -60.17. In terms of profitability, CBAY's ROE is -0.64%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CBAY is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
CBAY vs BPMC Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CBAY's ROE is -0.64%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CBAY is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
CBAY vs APGE Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas APGE's P/E ratio is -31.19. In terms of profitability, CBAY's ROE is -0.64%, compared to APGE's ROE of -0.30%. Regarding short-term risk, CBAY is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
CBAY vs CERE Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CERE's P/E ratio is -16.47. In terms of profitability, CBAY's ROE is -0.64%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CBAY is less volatile compared to CERE. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
CBAY vs IMVT Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while IMVT trades at $39.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas IMVT's P/E ratio is -13.92. In terms of profitability, CBAY's ROE is -0.64%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, CBAY is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
CBAY vs TXG Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, TXG has a market cap of 8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while TXG trades at $62.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TXG's P/E ratio is -106.19. In terms of profitability, CBAY's ROE is -0.64%, compared to TXG's ROE of -0.09%. Regarding short-term risk, CBAY is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
CBAY vs TWST Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, TWST has a market cap of 7.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while TWST trades at $124.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TWST's P/E ratio is -56.18. In terms of profitability, CBAY's ROE is -0.64%, compared to TWST's ROE of -0.30%. Regarding short-term risk, CBAY is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check TWST's competition here
Belite Bio, Inc (NASDAQ: BLTE)
CBAY vs BLTE Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, BLTE has a market cap of 7.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while BLTE trades at $193.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BLTE's P/E ratio is -103.53. In terms of profitability, CBAY's ROE is -0.64%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, CBAY is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check BLTE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
CBAY vs SYRE Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, SYRE has a market cap of 7.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while SYRE trades at $88.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SYRE's P/E ratio is -45.63. In terms of profitability, CBAY's ROE is -0.64%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, CBAY is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
CBAY vs MTSR Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CBAY's ROE is -0.64%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, CBAY is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
CBAY vs CAI Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, CAI has a market cap of 7.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while CAI trades at $25.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CAI's P/E ratio is 70.44. In terms of profitability, CBAY's ROE is -0.64%, compared to CAI's ROE of +0.19%. Regarding short-term risk, CBAY is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check CAI's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
CBAY vs RYTM Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while RYTM trades at $102.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RYTM's P/E ratio is -33.04. In terms of profitability, CBAY's ROE is -0.64%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, CBAY is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check RYTM's competition here
Merus N.V. (NASDAQ: MRUS)
CBAY vs MRUS Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CBAY's ROE is -0.64%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, CBAY is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
CBAY vs ACLX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CBAY's ROE is -0.64%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CBAY is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CBAY vs SRRK Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while SRRK trades at $55.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SRRK's P/E ratio is -16.04. In terms of profitability, CBAY's ROE is -0.64%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, CBAY is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
CBAY vs CGON Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while CGON trades at $74.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CGON's P/E ratio is -27.76. In terms of profitability, CBAY's ROE is -0.64%, compared to CGON's ROE of -0.25%. Regarding short-term risk, CBAY is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
CBAY vs RETA Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RETA's P/E ratio is -66.29. In terms of profitability, CBAY's ROE is -0.64%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CBAY is less volatile compared to RETA. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
CBAY vs CNTA Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CBAY's ROE is -0.64%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CBAY is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
CBAY vs MIRM Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while MIRM trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MIRM's P/E ratio is -6.93. In terms of profitability, CBAY's ROE is -0.64%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, CBAY is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check MIRM's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
CBAY vs TVTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while TVTX trades at $65.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TVTX's P/E ratio is -145.07. In terms of profitability, CBAY's ROE is -0.64%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, CBAY is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
CBAY vs DNTH Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while DNTH trades at $108.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas DNTH's P/E ratio is -26.05. In terms of profitability, CBAY's ROE is -0.64%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, CBAY is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
CBAY vs COGT Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while COGT trades at $34.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas COGT's P/E ratio is -16.47. In terms of profitability, CBAY's ROE is -0.64%, compared to COGT's ROE of -0.73%. Regarding short-term risk, CBAY is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
CBAY vs PTCT Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while PTCT trades at $69.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PTCT's P/E ratio is -29.74. In terms of profitability, CBAY's ROE is -0.64%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, CBAY is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check PTCT's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
CBAY vs XENE Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, XENE has a market cap of 5.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while XENE trades at $59.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas XENE's P/E ratio is -12.71. In terms of profitability, CBAY's ROE is -0.64%, compared to XENE's ROE of -0.44%. Regarding short-term risk, CBAY is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
CBAY vs LGND Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while LGND trades at $285.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas LGND's P/E ratio is 31.35. In terms of profitability, CBAY's ROE is -0.64%, compared to LGND's ROE of +0.20%. Regarding short-term risk, CBAY is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check LGND's competition here
Erasca, Inc. (NASDAQ: ERAS)
CBAY vs ERAS Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ERAS trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ERAS's P/E ratio is -17.41. In terms of profitability, CBAY's ROE is -0.64%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, CBAY is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ERAS's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
CBAY vs CDTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CBAY's ROE is -0.64%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, CBAY is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check CDTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
CBAY vs ORKA Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ORKA trades at $92.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ORKA's P/E ratio is -47.69. In terms of profitability, CBAY's ROE is -0.64%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, CBAY is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ORKA's competition here
Abcam plc (NASDAQ: ABCM)
CBAY vs ABCM Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CBAY's ROE is -0.64%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CBAY is less volatile compared to ABCM. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
CBAY vs ISEE Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CBAY's ROE is -0.64%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CBAY is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
CBAY vs CRSP Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while CRSP trades at $55.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CRSP's P/E ratio is -11.72. In terms of profitability, CBAY's ROE is -0.64%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, CBAY is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check CRSP's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
CBAY vs APLS Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas APLS's P/E ratio is 38.35. In terms of profitability, CBAY's ROE is -0.64%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CBAY is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
CBAY vs DFTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while DFTX trades at $38.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas DFTX's P/E ratio is N/A. In terms of profitability, CBAY's ROE is -0.64%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, CBAY is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check DFTX's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
CBAY vs ACAD Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ACAD trades at $28.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ACAD's P/E ratio is 12.62. In terms of profitability, CBAY's ROE is -0.64%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, CBAY is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ACAD's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
CBAY vs TERN Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TERN's P/E ratio is -51.41. In terms of profitability, CBAY's ROE is -0.64%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CBAY is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check TERN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
CBAY vs PBLS Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, PBLS has a market cap of 4.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while PBLS trades at $40.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PBLS's P/E ratio is -45.93. In terms of profitability, CBAY's ROE is -0.64%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, CBAY is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check PBLS's competition here
Celcuity Inc. (NASDAQ: CELC)
CBAY vs CELC Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, CELC has a market cap of 4.7B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while CELC trades at $95.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CELC's P/E ratio is -22.26. In terms of profitability, CBAY's ROE is -0.64%, compared to CELC's ROE of -3.51%. Regarding short-term risk, CBAY is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
CBAY vs EWTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, EWTX has a market cap of 4.6B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while EWTX trades at $43.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas EWTX's P/E ratio is -23.28. In terms of profitability, CBAY's ROE is -0.64%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, CBAY is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check EWTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
CBAY vs FOLD Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CBAY's ROE is -0.64%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CBAY is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check FOLD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
CBAY vs DYN Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, DYN has a market cap of 4.5B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while DYN trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas DYN's P/E ratio is -7.54. In terms of profitability, CBAY's ROE is -0.64%, compared to DYN's ROE of -0.64%. Regarding short-term risk, CBAY is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check DYN's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
CBAY vs AKRO Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CBAY's ROE is -0.64%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, CBAY is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
CBAY vs ALPN Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CBAY's ROE is -0.64%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CBAY is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
CBAY vs ELVN Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ELVN trades at $59.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ELVN's P/E ratio is -35.52. In terms of profitability, CBAY's ROE is -0.64%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, CBAY is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
CBAY vs OPT Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas OPT's P/E ratio is -1.52. In terms of profitability, CBAY's ROE is -0.64%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CBAY is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for CBAY.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
CBAY vs PRTC Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PRTC's P/E ratio is -3.78. In terms of profitability, CBAY's ROE is -0.64%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, CBAY is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check PRTC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
CBAY vs RLAY Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while RLAY trades at $19.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RLAY's P/E ratio is -12.13. In terms of profitability, CBAY's ROE is -0.64%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, CBAY is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
CBAY vs MRTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CBAY's ROE is -0.64%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CBAY is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check MRTX's competition here
Veradermics, Incorporated (NYSE: MANE)
CBAY vs MANE Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while MANE trades at $98.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MANE's P/E ratio is -31.34. In terms of profitability, CBAY's ROE is -0.64%, compared to MANE's ROE of -0.29%. Regarding short-term risk, CBAY is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check MANE's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
CBAY vs VKTX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas VKTX's P/E ratio is -7.48. In terms of profitability, CBAY's ROE is -0.64%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, CBAY is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check VKTX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
CBAY vs TLX Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while TLX trades at $11.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TLX's P/E ratio is 124.63. In terms of profitability, CBAY's ROE is -0.64%, compared to TLX's ROE of +0.07%. Regarding short-term risk, CBAY is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check TLX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
CBAY vs LEGN Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while LEGN trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas LEGN's P/E ratio is -31.65. In terms of profitability, CBAY's ROE is -0.64%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, CBAY is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check LEGN's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
CBAY vs IOVA Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, IOVA has a market cap of 3.9B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while IOVA trades at $8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas IOVA's P/E ratio is -12.04. In terms of profitability, CBAY's ROE is -0.64%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, CBAY is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check IOVA's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
CBAY vs TARS Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, TARS has a market cap of 3.9B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while TARS trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TARS's P/E ratio is -83.28. In terms of profitability, CBAY's ROE is -0.64%, compared to TARS's ROE of -0.14%. Regarding short-term risk, CBAY is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check TARS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
CBAY vs ADPT Comparison September 2026
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.7B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, CBAY is priced at $32.48 on the NASDAQ, while ADPT trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ADPT's P/E ratio is -59.22. In terms of profitability, CBAY's ROE is -0.64%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, CBAY is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for CBAY.Check ADPT's competition here